最新公告:

  没有公告

您现在的位置: 心灵之窗-眼科医生网 >> 眼科常识 >> 第11届全国会 >> 角膜结膜及泪器病11 >> 正文
专题栏目
更多内容
相关文章
更多内容
Prolongation of corneal allograft survival by topical application of Everolimus in a rat model         
Prolongation of corneal allograft survival by topical application of Everolimus in a rat model
作者:Li XQ, B… 文章来源:Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan, China 点击数:896 更新时间:2006/6/29 22:11:10
Background. Everolimus is a novel proliferation signal inhibitor with potent immunosuppressant effects that holds promise to prevent acute allograft rejection. Commonly, topical application of immune modulatory agents is preferred to its systemic use to reduce side effects of the drug. Purpose. Here we evaluated the efficacy of topical administration of Everolimus on experimental corneal grafts. Methods. A total of 16 female Lewis rats received 3.5 mm MHC I/II incompatible corneal grafts of DA donors. Recipients were randomly assigned to receive either, 0.05% Everolimus in a microemulsion formulation (1) or the drug vehicle (2) as control. All treatments were started at the day of surgery and applied five times daily for 35 days. Grafts were graded every day and a rejection score was generated based on cornea clarity and oedema. Results. Local administration of Everolimus was effective in prolonging the mean survival time of corneal grafts (MST 21 +/- 7.4 days) as compared to vehicle control group (13.3+/- 1.7 days; p=0.013). Conclusions. These data indicate that topically applied Everolimus significantly prolonged the corneal allograft survival in an experimental keratoplasty model. (Supported in part by DFG Pl 150-14/2)
会议投稿录入:xq.lee    责任编辑:毛进 
  • 上一篇会议投稿:

  • 下一篇会议投稿:
  • 【字体: 】【发表评论】【加入收藏】【告诉好友】【打印此文】【关闭窗口
      网友评论:(只显示最新10条。评论内容只代表网友观点,与本站立场无关!)

    | 设为首页 | 加入收藏 | 联系站长 | 友情链接 | 版权申明 |
    眼科医生网 眼科医生网版权所有 @ 1998-2012
    部分文章和资源来源于网络,如果侵犯了您的版权,请指出! 站长:毛进
    信息产业部备案
    *京ICP备18030162号